Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* use of lopinavir 400mg/ritonavir 100mg bid \> 3months~* HIV-1 RNA \<400cop/mL~* fasting total cholesterol \> 6.2mmol/L~Exclusion Criteria:~* history of sensitivity/idiosyncrasy to the drug or compounds used~* history or current condition that might interfere with absorption,distribution metabolism or excretion~* pregnant or breast-feeding~* serum transaminase levels \>3 times upper limit of normal, creatinine clearance \<60ml/min~* fasting plasma triglycerides level \>8.0 mmol/L~* history of statin-related rhabdomyolysis or inheritable muscle diseases in family history~* clinical symptoms of myopathy or abnormal CK level~* change in antiretroviral medication within the 3 months immediately preceding first dose of rosuvastatin~* use of any statin or fibrate within 6 weeks immediately preceding first dose of rosuvastatin~* concomitant use of medications that interfere with rosuvastatin or lopinavir pharmacokinetics~* active hepatobiliary or hepatic disease~* hypothyroidism~* alcohol abuse~* japanese or chinese patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).